Galway medtech firm eyes US launch for cancer patient device

SymPhysis raised €2.8m in its latest funding round and expects to close a further €3.7m from a combination of current and new investors by April 2025

Announcing SymPhysis Medical’s team as it prepares for its US launch are, from left: Gerard Ryan, board member; Michelle Tierney, co-founder and chief scientific officer; and Tim Jones, co-founder and CEO.

Galway medtech company SymPhysis Medical is targeting revenues of €40m by 2030 as the company prepares a US launch for its device which clears fluid from the chests of cancer patients.

The company hopes to secure clearance from the US Food and Drug Administration (FDA) targeted by 2026. The Releaze device can be used by cancer patients who are receiving palliative care to relieve symptoms of fluid in the chest, including shortness of breath, discomfort, and pain.